Molecular Epidemiology, Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.
Department of Orthopaedics, Leiden University Medical Center, Leiden, the Netherlands.
Osteoarthritis Cartilage. 2021 Aug;29(8):1193-1202. doi: 10.1016/j.joca.2021.05.001. Epub 2021 May 10.
We here aimed to characterize changes of Matrix Gla Protein (MGP) expression in relation to its recently identified OA risk allele rs1800801-T in OA cartilage, subchondral bone and human ex vivo osteochondral explants subjected to OA related stimuli. Given that MGP function depends on vitamin K bioavailability, we studied the effect of frequently prescribed vitamin K antagonist warfarin.
Differential (allelic) mRNA expression of MGP was analyzed using RNA-sequencing data of human OA cartilage and subchondral bone. Human osteochondral explants were used to study exposures to interleukin one beta (IL-1β; inflammation), triiodothyronine (T3; Hypertrophy), warfarin, or 65% mechanical stress (65%MS) as function of rs1800801 genotypes.
We confirmed that the MGP risk allele rs1800801-T was associated with lower expression and that MGP was significantly upregulated in lesioned as compared to preserved OA tissues, mainly in risk allele carriers, in both cartilage and subchondral bone. Moreover, MGP expression was downregulated in response to OA like triggers in cartilage and subchondral bone and this effect might be reduced in carriers of the rs1800801-T risk allele. Finally, warfarin treatment in cartilage increased COL10A1 and reduced SOX9 and MMP3 expression and in subchondral bone reduced COL1A1 and POSTN expression.
DISCUSSION & CONCLUSIONS: Our data highlights that the genetic risk allele lowers MGP expression and upon OA relevant triggers may hamper adequate dynamic changes in MGP expression, mainly in cartilage. The determined direct negative effect of warfarin on human explant cultures functionally underscores the previously found association between vitamin K deficiency and OA.
本研究旨在探讨骨钙素(MGP)表达的变化与 OA 软骨、软骨下骨及经 OA 相关刺激的人离体骨软骨样本中其最近发现的 OA 风险等位基因 rs1800801-T 之间的关系。由于 MGP 的功能取决于维生素 K 的生物利用度,我们研究了经常开处方的维生素 K 拮抗剂华法林的作用。
采用 RNA 测序数据分析人 OA 软骨和软骨下骨的 MGP 差异(等位)mRNA 表达。用人离体骨软骨样本研究白细胞介素 1β(IL-1β;炎症)、三碘甲状腺原氨酸(T3;肥大)、华法林或 65%机械应力(65%MS)对 rs1800801 基因型的影响。
我们证实,MGP 风险等位基因 rs1800801-T 与表达降低相关,且 MGP 在病变 OA 组织中显著上调,与对照组织相比,在软骨和软骨下骨中,主要在风险等位基因携带者中上调。此外,MGP 表达在软骨和软骨下骨中对 OA 样触发因素呈下调趋势,而这种效应在 rs1800801-T 风险等位基因携带者中可能降低。最后,华法林治疗软骨增加 COL10A1 并减少 SOX9 和 MMP3 表达,在软骨下骨减少 COL1A1 和 POSTN 表达。
我们的数据强调,遗传风险等位基因降低了 MGP 的表达,并且在 OA 相关触发因素下,可能会阻碍 MGP 表达的充分动态变化,主要在软骨中。华法林对人离体培养物的直接负向作用,从功能上验证了先前发现的维生素 K 缺乏与 OA 之间的关联。